B-crobes Hexbio Slashes Cancer & Diabetes Risk

One of Malaysia's top supplements industry players, B-Crobes Laboratory Sdn. Bhd. (B-Crobes), has unveiled its latest medical breakthrough research into the probiotic BCMC® strains. These strains are being studied as a complementary therapy for non-communicable diseases (NCDs), and B-Crobes recently showcased newly discovered studies on the application of BCMC® strains at a press conference held in conjunction with the Gut Research Group, Faculty of Medicine, Universiti Kebangsaan Malaysia (UKM). These studies have shown that BCMC® strains are effective in managing NCDs such as Colorectal Cancer, Post-Gestational Diabetes (Women who have just delivered with Diabetes), and Non-Alcoholic Fatty Liver Disease (NAFLD). B-Crobes has been conducting research, development, and manufacturing of specific strains of probiotics for over 20 years. The BCMC® strains have been clinically tested and proven to be safe and effective, leading to their use in government hospitals and clinics across Malaysia. They are also sold internationally in countries like UAE, Bahrain, China, Oman, Singapore, Philippines, and many more.

During the press conference, B-Crobes presented several studies. One study, “A Randomized Double-Blind Placebo-Controlled Trial on Post-Surgical Colorectal Cancer Patients,” investigated the effects of BCMC® strains on post-surgical colorectal patients. Patients were divided into two groups, one receiving a placebo and the other receiving BCMC® strains at random, for a 6-month recovery period. It was found that BCMC® strains led to a significant reduction in the levels of specific pro-inflammatory cytokines, which are harmful substances that are known to cause poor outcomes and contribute to the development and recurrence of cancer in patients with colorectal cancer, thus improving the recovery rate of post-surgical colorectal cancer.

Another study presented, “The Roles of Probiotics in the Gut Microbiots Composition Outcomes in Asymptomatic Post-Gestational Diabetes Women: A Randomized Controlled Trial,” investigated the effects of BCMC® strains on glucose metabolism in postpartum women with a history of gestational diabetes mellitus (GDM). Participants were divided into two groups, one receiving a placebo and the other receiving BCMC® strains at random, for a total of three months. It was found that the group supplied with BCMC® strains had significant improvements in their insulin resistance, which plays an important factor in managing post-gestational diabetes and decreasing the risk of developing Type 2 diabetes.

The studies on NAFLD included two studies: “The Effect of Probiotics (MCP® BCMC® Strains) on Hepatic Steatosis, Small Intestinal Mucosal Immune Function, and Intestinal Barrier in Patients with Non-Alcoholic Fatty Liver Disease” and “The Effects of Probiotics on Small Intestinal Microbiota Composition, Inflammatory Cytokines and Intestinal Permeability in Patients with Non-Alcoholic Fatty Liver Disease.” Researchers investigated the effects of BCMC® strains on hepatic steatosis, fibrosis, and biochemical blood tests in patients with NAFLD. The study was done through a blind trial with two groups of patients, supplied with a placebo and BCMC® strains at random, for a total of six months. Once the trial was concluded, it was found that the BCMC® strains managed to stabilize the mucosal immune function which protects NAFLD patients against intestinal permeability (preventing toxins from entering). In addition to this, the consumption of BCMC® strains also leads to a well-balanced microbiota composition, resulting in a healthy gut that deemed the BCMC® strains a complementary role in treating NAFLD.

According to Mrs. Razida Hanim Abdul Razak, Director of Lifestyle & Sciences Section at Malaysia External Trade Development Corporation (MATRADE), the recent research collaboration between B-Crobes and local universities showcases the dedication of industry leaders to provide effective and clinically developed health products for Malaysians. This collaboration also helps to enhance the demand and reliability of Malaysian-made products on the global market.

Aligned with the Ministry of Health’s National Strategic Plan, B-Crobes has signed a research agreement with UKM and Sunway University to collaborate on the clinical application of BCMC® strains and gut microbiomes in health. As part of this initiative, B-Crobes has provided educational research grants and scholarships to two full-time Ph.D. students, one at each university.

Mrs. Razida Hanim believes that this collaboration will nurture Malaysia's medical and pharmaceutical industry, motivating local players to discover new findings that will benefit mankind and position Malaysia as a reputable and reliable source for medical products worldwide. Mr. Dean Lee, Executive Director of B-Crobes Group of Companies, sees this initiative as an example of a quadruple-helix collaboration in clinical research and development, involving industry, universities, government, and the public.

B-Crobes is also excited to announce the development of a new research facility in Batu Kawan, Penang, set to open in 2025, following the success of previous HEXBIO products used locally and internationally. The company is committed to improving the health of Malaysians and will continue to strive for new medical discoveries that contribute to society.

For more information, visit https://bcrobes.com/about-us

Watch Video

Video powered by Dubb